Skip to main content

Table 2 Clinical trials using proteomic analysis

From: Genomic and proteomic approaches for studying human cancer: Prospects for true patient-tailored therapy

Sponsor

Principal investigator, centre

Disease, application

NCI

Elise Kohn, Warren Grant Magnuson Clinical Center, NIH, Bethesda, MD, USA

Ovarian cancer, developing serum proteomic profile associated with first clinical response

NCI

Elise Kohn, Warren Grant Magnuson Clinical Center, NIH, Bethesda, MD, USA

Breast and ovarian cancer, protein microarray to assess response to EGFR inhibitors and Gleevac

NCI

Susan Bates, Warren Grant Magnuson Clinical Center, NIH, Bethesda, MD, USA

Breast and ovarian cancer, protein microarray to assess response to Herceptin/Taxol combination therapy

NCI

Sam Hwang, Warren Grant Magnuson Clinical Center, NIH, Bethesda, MD, USA

Inflammatory and neoplastic skin diseases, developing serum proteomic profile for diagnosis

NCI

Michael Solomon, Warren Grant Magnuson Clinical Center, NIH, Bethesda, MD, USA

Cardiac disease, developing serum proteomic profile for diagnosis of acute cardiac allograft rejection

NCI

Mahrukh Hussain, Warren Grant Magnuson Clinical Center, NIH, Bethesda, MD, USA

Ovarian cancer, developing serum proteomic profile associated with relapse

  1. Abbreviations: EGFR, epidermal growth factor receptor